Gallant Therapeutics is pioneering the field of veterinary medicine by advancing stem cell therapy to close the innovation gap between human and animal health. The company focuses on mesenchymal stem cells (MSCs) derived from adult tissues, specifically the uterus, which can differentiate into various cell types such as bone, cartilage, muscle, and fat cells. Gallant's cell therapy platform has generated a pipeline of allogeneic products targeting four key indications and holds five investigational new animal drug applications (INADs). The company also participates in the FDA Center for Veterinary Medicine's Veterinary Innovation Program, which supports the development of innovative therapies. Gallant's business model revolves around fast-tracking impactful regenerative medicine products to transform animal health, serving pet owners and veterinary professionals. The company operates in the veterinary medicine market, which saw a 60% increase in expenditure from 1998 to 2018 and is part of the $119 billion pet industry. Gallant generates revenue through the development and commercialization of its stem cell therapy products.

Keywords: stem cell therapy, veterinary medicine, regenerative solutions, mesenchymal stem cells, allogeneic products, FDA approval, innovation, pet health, veterinary innovation, regenerative medicine.